Epstein-Barr Virus Infection

Thomas' Hematopoietic Cell Transplantation: Stem Cell Transplantation, Fourth Edition

Volumn , Issue , 2009, Pages 1410-1418

  Hsieh, Wen Son ^a   Ambinder, Richard F ^a  

^a JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

QFD "customer driven product service development"; Quality function deployment (QFD); Satisfying external customers; Understanding customer needs

Indexed keywords

EID: 84884181987     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1002/9781444303537.ch93     Document Type: Chapter

References (98)

1. Rickinson AB, Kieff E. Epstein-Barr virus. In: Knipe DM, Howley PM, editors. Field's Virology, 5th edn. Philadelphia: Lippincott Williams & Wilkins; 2007. pp. 2655-700.
2. Ambinder RF, Cesarman E. Clinical and pathological aspects of EBV and KSHV infection. In: Arvin A, Campadelli-Fiume G, Moore PS, editors. Human Herpesviruses Biology, Therapy, and Immunoprophylaxis. New York: Cambridge University Press; 2007. pp. 885-914.
3. Cohen JI. Epstein-Barr virus infection. N Engl J Med 2000; 343: 481-92.
4. Tomkinson BE, Wagner DK, Nelson DL, Sullivan JL. Activated lymphocytes during acute Epstein-Barr virus infection. J Immunol 1987; 139: 3802-7.
5. Precopio ML, Sullivan JL, Willard C, Somasundaran M, Luzuriaga K. Differential kinetics and specificity of EBV-specific CD4+ and CD8+ T cells during primary infection. J Immunol 2003; 170: 2590-8.
6. Woodberry T, Suscovich TJ, Henry LM et al. Differential targeting and shifts in the immunodominance of Epstein-Barr virus-specific CD8 and CD4 T-cell responses during acute and persistent infection. J Infect Dis 2005; 192: 1513-24.
7. Amyes E, Hatton C, Montamat-Sicotte D et al. Characterization of the CD4+ T-cell response to Epstein-Barr virus during primary and persistent infection. J Exp Med 2003; 198: 903-11.
8. Williams H, Crawford DH. Epstein-Barr virus: the impact of scientific advances on clinical practice. Blood 2006; 107: 862-9.
9. Sauce D, Larsen M, Curnow SJ et al. EBV-associated mononucleosis leads to long-term global deficit in T-cell responsiveness to IL-15. Blood 2006; 108: 11-18.
10. Lemas MV, Ambinder RF. The kiss that scars. Blood 2006; 108: 8.
11. Hjalgrim H, Smedby KE, Rostgaard K et al. Infectious mononucleosis, childhood social environment, and risk of Hodgkin lymphoma. Cancer Res 2007; 67: 2382-8.
12. Hjalgrim H, Askling J, Rostgaard K et al. Characteristics of Hodgkin's lymphoma after infectious mononucleosis. N Engl J Med 2003; 349: 1324-32.
13. Huang J, Chen H, Hutt-Fletcher L, Ambinder RF, Hayward SD. Lytic viral replication as a contributor to the detection of Epstein-Barr virus in breast cancer. J Virol 2003; 77: 13267-74.
14. Glaser SL, Ambinder RF, DiGiuseppe JA, Horn-Ross PL, Hsu JL. Absence of Epstein-Barr virus EBER-1 transcripts in an epidemiologically diverse group of breast cancers. Int J Cancer 1998; 75: 555-8.
15. Meijer E, Slaper-Cortenbach IC, Thijsen SF, Dekker AW, Verdonck LF. Increased incidence of EBV-associated lymphoproliferative disorders after allogeneic stem cell transplantation from matched unrelated donors due to a change of T-cell depletion technique. Bone Marrow Transplant 2002; 29: 335-9.
16. Curtis RE, Travis LB, Rowlings PA et al. Risk of lymphoproliferative disorders after bone marrow transplantation: a multi-institutional study. Blood 1999; 94: 2208-16.
17. Gross TG, Hinrichs SH, Davis JR, Mitchell D, Bishop MR, Wagner JE. Depletion of EBVinfected cells in donor marrow by counterflow elutriation. Exp Hematol 1998; 26: 395-9.
18. Lucas KG, Small TN, Heller G, Dupont B, O'Reilly RJ. The development of cellular immunity to Epstein-Barr virus after allogeneic bone marrow transplantation. Blood 1996; 87: 2594-603.
19. Zutter MM, Durnam DM, Hackman RC et al. Secondary T-cell lymphoproliferation after marrow transplantation. Am J Clin Pathol 1990; 94: 714-21.
20. Trimble MS, Waye JS, Walker IR, Brain MC, Leber BF. B-cell lymphoma of recipient origin 9 years after allogeneic bone marrow transplantation for T-cell acute lymphoblastic leukaemia. Br J Haematol 1993; 85: 99-102.
21. Leblond V, Davi F, Charlotte F et al. Posttransplant lymphoproliferative disorders not associated with Epstein-Barr virus: a distinct entity?. J Clin Oncol 1998; 16: 2052-9.
22. Biggar RJ, Jaffe ES, Goedert JJ, Chaturvedi A, Pfeiffer R, Engels EA. Hodgkin lymphoma and immunodeficiency in persons with HIV/AIDS. Blood 2006; 108: 3786-91.
23. Gross TG, Steinbuch M, DeFor T et al. B cell lymphoproliferative disorders following hematopoietic stem cell transplantation: risk factors, treatment and outcome. Bone Marrow Transplant 1999; 23: 251-8.
24. Ho AY, Adams S, Shaikh H, Pagliuca A, Devereux S, Mufti GJ. Fatal donor-derived Epstein-Barr virus-associated post-transplant lymphoproliferative disorder following reduced intensity volunteer-unrelated bone marrow transplant for myelodysplastic syndrome. Bone Marrow Transplant 2002; 29: 867-9.
25. Milpied N, Coste-Burel M, Accard F et al. Epstein-Barr virus-associated B cell lymphoproliferative disease after non-myeloablative allogeneic stem cell transplantation. Bone Marrow Transplant 1999; 23: 629-30.
26. Shields DJ, Byrd JC, Abbondanzo SL, Lichy JH, Diehl LF, Aguilera NI. Detection of Epstein-Barr virus in transformations of low-grade B-cell lymphomas after fludarabine treatment. Mod Pathol 1997; 10: 1151-9.
27. Abruzzo LV, Rosales CM, Medeiros LJ et al. Epstein-Barr virus-positive B-cell lymphoproliferative disorders arising in immunodeficient patients previously treated with fludarabine for low-grade B-cell neoplasms. Am J Surg Pathol 2002; 26: 630-6.
28. Barker JN, Martin PL, Coad JE et al. Low incidence of Epstein-Barr virus-associated posttransplantation lymphoproliferative disorders in 272 unrelated-donor umbilical cord blood transplant recipients. Biol Blood Marrow Transplant 2001; 7: 395-9.
29. Ohga S, Kanaya Y, Maki H et al. Epstein-Barr virusassociated lymphoproliferative disease after a cord blood transplant for Diamond-Blackfan anemia. Bone Marrow Transplant 2000; 25: 209-12.
30. Brunstein CG, Weisdorf DJ, DeFor T et al. Marked increased risk of Epstein-Barr virus-related complications with the addition of antithymocyte globulin to a nonmyeloablative conditioning prior to unrelated umbilical cord blood transplantation. Blood 2006; 108: 2874-80.
31. Anderson KC, Soiffer R, DeLage R et al. T-celldepleted autologous bone marrow transplantation therapy: analysis of immune deficiency and late complications. Blood 1990; 76: 235-44.
32. Peniket AJ, Perry AR, Williams CD et al. A case of EBV-associated lymphoproliferative disease following high-dose therapy and CD34-purified autologous peripheral blood progenitor cell transplantation. Bone Marrow Transplant 1998; 22: 307-9.
33. Lones MA, Kirov I, Said JW, Shintaku IP, Neudorf S. Post-transplant lymphoproliferative disorder after autologous peripheral stem cell transplantation in a pediatric patient. Bone Marrow Transplant 2000; 26: 1021-4.
34. Nolte A, Buhmann R, Emmerich B, Schendel D, Hallek M. Reconstitution of the cellular immune response after autologous peripheral blood stem cell transplantation in patients with non-Hodgkin's lymphoma. Br J Haematol 2000; 108: 415-23.
35. Nolte A, Buhmann R, Straka C, Emmerich B, Hallek M. Assessment and characterization of the cytolytic T lymphocyte response against Epstein-Barr virus in patients with non-Hodgkin's lymphoma after autologous peripheral blood stem cell transplantation. Bone Marrow Transplant 1998; 21: 909-16.
36. Hislop AD, Annels NE, Gudgeon NH, Leese AM, Rickinson AB. Epitope-specific evolution of human CD8(+) T-cell responses from primary to persistent phases of Epstein-Barr virus infection. J Exp Med 2002; 195: 893-905.
37. Redchenko IV, Rickinson AB. Accessing Epstein-Barr virus-specific T-cell memory with peptideloaded dendritic cells. J Virol 1999; 73: 334-42.
38. Annels NE, Callan MF, Tan L, Rickinson AB. Changing patterns of dominant TCR usage with maturation of an EBV-specific cytotoxic T-cell response. J Immunol 2000; 165: 4831-41.
39. Marshall NA, Howe JG, Formica R et al. Rapid reconstitution of Epstein-Barr virus-specific T lymphocytes following allogeneic stem cell transplantation. Blood 2000; 96: 2814-21.
40. Meij P, van Esser JW, Niesters HG et al. Impaired recovery of Epstein-Barr virus (EBV)-specific CD8+ T lymphocytes after partially T-depleted allogeneic stem cell transplantation may identify patients at very high-risk for progressive EBV reactivation and lymphoproliferative disease. Blood 2003; 101: 4290-7.
41. van Baarle D, Hovenkamp E, Callan MF et al. Dysfunctional Epstein-Barr virus (EBV)-specific CD8(+) T lymphocytes and increased EBV load in HIV-1 infected individuals progressing to AIDSrelated non-Hodgkin lymphoma. Blood 2001; 98: 146-55.
42. Piriou E, van Dort K, Nanlohy NM, van Oers MH, Miedema F, van Baarle D. Loss of EBNA1-specific memory CD4+ and CD8+ T cells in HIV-infected patients progressing to AIDS-related non-Hodgkin lymphoma. Blood 2005; 106: 3166-74.
43. Nikiforow S, Bottomly K, Miller G. CD4+ T-cell effectors inhibit Epstein-Barr virus-induced B-cell proliferation. J Virol 2001; 75: 3740-52.
44. Munz C, Bickham KL, Subklewe M et al. Human CD4(+) T lymphocytes consistently respond to the latent Epstein-Barr virus nuclear antigen EBNA1. J Exp Med 2000; 191: 1649-60.
45. Chadburn A, Chen JM, Hsu DT et al. The morphologic and molecular genetic categories of posttransplantation lymphoproliferative disorders are clinically relevant. Cancer 1998; 82: 1978-87.
46. Knowles DM, Cesarman E, Chadburn A et al. Correlative morphologic and molecular genetic analysis demonstrates three distinct categories of posttransplantation lymphoproliferative disorders. Blood 1995; 85: 552-65.
47. Harris NL, Ferry JA, Swerdlow SH. Posttransplant lymphoproliferative disorders: summary of Society for Hematopathology Workshop. Semin Diagn Pathol 1997; 14: 8-14.
48. Swerdlow SH. Classification of the posttransplant lymphoproliferative disorders: from the past to the present. Semin Diagn Pathol 1997; 14: 2-7.
49. Jaffe ES, Harris NL, Stein H, Vardiman JW. Pathology and Genetics of Tumours of Haematopoietic and Lymphoid Tissues. World Health Organization Classification of Tumours. Lyon: IARC Press; 2001.
50. Knowles DM. Immunodeficiency-associated lymphoproliferative disorders. Mod Pathol 1999; 12: 200-17.
51. Gratama JW, Oosterveer MA, Zwaan FE, Lepoutre J, Klein G, Ernberg I. Eradication of Epstein-Barr virus by allogeneic bone marrow transplantation: implications for sites of viral latency. Proc Natl Acad Sci U S A 1988; 85: 8693-6.
52. Faulkner GC, Burrows SR, Khanna R, Moss DJ, Bird AG, Crawford DH. X-Linked agammaglobulinemia patients are not infected with Epstein-Barr virus: implications for the biology of the virus. J Virol 1999; 73: 1555-64.
53. Frank D, Cesarman E, Liu YF, Michler RE, Knowles DM. Posttransplantation lymphoproliferative disorders frequently contain type A and not type B Epstein-Barr virus. Blood 1995; 85: 1396-403.
54. Tao Q, Yang J, Huang H, Swinnen LJ, Ambinder RF. Conservation of Epstein-Barr virus cytotoxic T-cell epitopes in posttransplant lymphomas: implications for immune therapy. Am J Pathol 2002; 160: 1839-45.
55. Murray PG, Swinnen LJ, Constandinou CM et al. BCL-2 but not its Epstein-Barr virus-encoded homologue, BHRF1, is commonly expressed in posttransplantation lymphoproliferative disorders. Blood 1996; 87: 706-11.
56. Gottschalk S, Ng CY, Perez M et al. An Epstein-Barr virus deletion mutant associated with fatal lymphoproliferative disease unresponsive to therapy with virus-specific CTLs. Blood 2001; 97: 835-43.
57. Yang J, Tao Q, Flinn IW et al. Characterization of Epstein-Barr virus-infected B cells in patients with posttransplantation lymphoproliferative disease: disappearance after rituximab therapy does not predict clinical response. Blood 2000; 96: 4055-63.
58. Rose C, Green M, Webber S et al. Detection of Epstein-Barr virus genomes in peripheral blood B cells from solid-organ transplant recipients by fluorescence in situ hybridization. J Clin Microbiol 2002; 40: 2533-44.
59. Johannessen I, Haque T, N'Jie-Jobe J, Crawford DH. Non-correlation of in vivo and in vitro parameters of Epstein-Barr virus persistence suggests heterogeneity of B cell infection. J Gen Virol 1998; 79(Pt 7): 1631-6.
60. Orii T, Ohkohchi N, Satomi S, Hoshino Y, Kimura H. Decreasing the Epstein-Barr virus load by adjusting the FK506 blood level. Transplant Int 2002; 15: 529-34.
61. Holmes RD, Orban-Eller K, Karrer FR, Rowe DT, Narkewicz MR, Sokol RJ. Response of elevated Epstein-Barr virus DNA levels to therapeutic changes in pediatric liver transplant patients: 56-month follow up and outcome. Transplantation 2002; 74: 367-72.
62. Green M. Management of Epstein-Barr virusinduced post-transplant lymphoproliferative disease in recipients of solid organ transplantation. Am J Transplant 2001; 1: 103-8.
63. Wagner HJ, Cheng YC, Huls MH et al. Prompt versus preemptive intervention for EBV lymphoproliferative disease. Blood 2004; 103: 3979-81.
64. van Esser JW, Niesters HG, Thijsen SF et al. Molecular quantification of viral load in plasma allows for fast and accurate prediction of response to therapy of Epstein-Barr virus-associated lymphoproliferative disease after allogeneic stem cell transplantation. Br J Haematol 2001; 113: 814-21.
65. van Esser JW, van der Holt B, Meijer E et al. Epstein-Barr virus (EBV) reactivation is a frequent event after allogeneic stem cell transplantation (SCT) and quantitatively predicts EBV-lymphoproliferative disease following T-cell-depleted SCT. Blood 2001; 98: 972-8.
66. van Esser JW, Niesters HG, van der Holt B et al. Prevention of Epstein-Barr virus-lymphoproliferative disease by molecular monitoring and preemptive rituximab in high-risk patients after allogeneic stem cell transplantation. Blood 2002; 99: 4364-9.
67. Chan AT, Lo YM, Zee B et al. Plasma Epstein-Barr virus DNA and residual disease after radiotherapy for undifferentiated nasopharyngeal carcinoma. J Natl Cancer Inst 2002; 94: 1614-19.
68. Johnson PJ, Lo YM. Plasma nucleic acids in the diagnosis and management of malignant disease. Clin Chem 2002; 48: 1186-93.
69. Au WY, Pang A, Choy C, Chim CS, Kwong YL. Quantification of circulating Epstein-Barr virus (EBV) DNA in the diagnosis and monitoring of natural killer cell and EBV-positive lymphomas in immunocompetent patients. Blood 2004; 104: 243-9.
70. Gandhi MK, Lambley E, Burrows J et al. Plasma Epstein-Barr virus (EBV) DNA is a biomarker for EBV-positive Hodgkin's lymphoma. Clin Cancer Res 2006; 12: 460-4.
71. Oertel S, Trappe RU, Zeidler K et al. Epstein-Barr viral load in whole blood of adults with posttransplant lymphoproliferative disorder after solid organ transplantation does not correlate with clinical course. Ann Hematol 2006; 85: 478-84.
72. Stevens SJ, Verschuuren EA, Verkuujlen SA, Van Den Brule AJ, Meijer CJ, Middeldorp JM. Role of Epstein-Barr virus DNA load monitoring in prevention and early detection of post-transplant lymphoproliferative disease. Leuk Lymphoma 2002; 43: 831-40.
73. Wagner HJ, Rooney CM, Heslop HE. Diagnosis and treatment of posttransplantation lymphoproliferative disease after hematopoietic stem cell transplantation. Biol Blood Marrow Transplant 2002; 8: 1-8.
74. Zutter MM, Martin PJ, Sale GE et al. Epstein-Barr virus lymphoproliferation after bone marrow transplantation. Blood 1988; 72: 520-9.
75. Loren AW, Porter DL, Stadtmauer EA, Tsai DE. Post-transplant lymphoproliferative disorder: a review. Bone Marrow Transplant 2003; 31: 145-55.
76. Swinnen LJ, Mullen GM, Carr TJ, Costanzo MR, Fisher RI. Aggressive treatment for postcardiac transplant lymphoproliferation. Blood 1995; 86: 3333-40.
77. Papadopoulos EB, Ladanyi M, Emanuel D et al. Infusions of donor leukocytes to treat Epstein-Barr virus-associated lymphoproliferative disorders after allogeneic bone marrow transplantation. N Engl J Med 1994; 330: 1185-91.
78. Chiang KY, Hazlett LJ, Godder KT et al. Epstein-Barr virus-associated B cell lymphoproliferative disorder following mismatched related T celldepleted bone marrow transplantation. Bone Marrow Transplant 2001; 28: 1117-23.
79. Rooney CM, Smith CA, Ng CY et al. Infusion of cytotoxic T cells for the prevention and treatment of Epstein-Barr virus-induced lymphoma in allogeneic transplant recipients. Blood 1998; 92: 1549-55.
80. Liu Z, Savoldo B, Huls H et al. Epstein-Barr virus (EBV)-specific cytotoxic T lymphocytes for the prevention and treatment of EBV-associated posttransplant lymphomas. Recent Results Cancer Res 2002; 159: 123-33.
81. Choquet S, Leblond V, Herbrecht R et al. Efficacy and safety of rituximab in B-cell post-transplantation lymphoproliferative disorders: results of a prospective multicenter phase 2 study. Blood 2006; 107: 3053-7.
82. Kuehnle I, Huls MH, Liu Z et al. CD20 monoclonal antibody (rituximab) for therapy of Epstein-Barr virus lymphoma after hemopoietic stem-cell transplantation. Blood 2000; 95: 1502-5.
83. Swinnen LJ. Immune-cell treatment of Epstein-Barr-virus-associated lymphoproliferative disorders. Best Pract Res Clin Haematol 2006; 19: 839-47.
84. Comoli P, Basso S, Zecca M et al. Preemptive therapy of EBV-related lymphoproliferative disease after pediatric haploidentical stem cell transplantation. Am J Transplant 2007; 7: 1648-55.
85. Rowlings PA, Curtis RE, Passweg JR et al. Increased incidence of Hodgkin's disease after allogeneic bone marrow transplantation. J Clin Oncol 1999; 17: 3122-7.
86. Murray PG, Constandinou CM, Crocker J, Young LS, Ambinder RF. Analysis of major histocompatibility complex class I, TAP expression, and LMP2 epitope sequence in Epstein-Barr virus-positive Hodgkin's disease. Blood 1998; 92: 2477-83.
87. Sing AP, Ambinder RF, Hong DJ et al. Isolation of Epstein-Barr virus (EBV)-specific cytotoxic T lymphocytes that lyse Reed-Sternberg cells: implications for immune-mediated therapy of EBV+ Hodgkin's disease. Blood 1997; 89: 1978-86.
88. Marshall NA, Christie LE, Munro LR et al. Immunosuppressive regulatory T cells are abundant in the reactive lymphocytes of Hodgkin lymphoma. Blood 2004; 103: 1755-62.
89. Marshall NA, Culligan DJ, Tighe J, Johnston PW, Barker RN, Vickers MA. The relationships between Epstein-Barr virus latent membrane protein 1 and regulatory T cells in Hodgkin's lymphoma. Exp Hematol 2007; 35: 596-604.
90. Gandhi MK, Lambley E, Duraiswamy J et al. Expression of LAG-3 by tumor-infiltrating lymphocytes is coincident with the suppression of latent membrane antigen-specific CD8+ T-cell function in Hodgkin lymphoma patients. Blood 2006; 108: 2280-9.
91. Savoldo B, Goss JA, Hammer MM et al. Treatment of solid organ transplant recipients with autologous Epstein Barr virus-specific cytotoxic T lymphocytes (CTLs). Blood 2006; 108: 2942-9.
92. Haque T, Wilkie GM, Jones MM et al. Allogeneic cytotoxic T-cell therapy for EBV-positive post transplant lymphoproliferative disease: results of a phase II multicentre clinical trial. Blood 2007; 93: 1123-31.
93. Bollard CM, Aguilar L, Straathof KC et al. Cytotoxic T lymphocyte therapy for Epstein-Barr virus+ Hodgkin's disease. J Exp Med 2004; 200: 1623-33.
94. Comoli P, Pedrazzoli P, Maccario R et al. Cell therapy of stage IV nasopharyngeal carcinoma with autologous Epstein-Barr virus-targeted cytotoxic T lymphocytes. J Clin Oncol 2005; 23: 8942-9.
95. Straathof KC, Bollard CM, Popat U et al. Treatment of nasopharyngeal carcinoma with Epstein-Barr virus-specific T lymphocytes. Blood 2005; 105: 1898-904.
96. Bollard CM, Gottschalk S, Huls MH et al. In vivo expansion of LMP 1-and 2-specific T-cells in a patient who received donor-derived EBV-specific T-cells after allogeneic stem cell transplantation. Leuk Lymphoma 2006; 47: 837-42.
97. Savoldo B, Rooney CM, Di Stasi A et al. Epstein Barr virus specific cytotoxic T lymphocytes expressing the anti-CD30zeta artificial chimeric Tcell receptor for immunotherapy of Hodgkin disease. Blood 2007; 110: 2620-30.
98. Jurgens LA, Khanna R, Weber J, Orentas RJ. Transduction of primary lymphocytes with Epstein-Barr virus (EBV) latent membrane protein-specific T-cell receptor induces lysis of virus-infected cells: a novel strategy for the treatment of Hodgkin's disease and nasopharyngeal carcinoma. J Clin Immunol 2006; 26: 22-32.